Downregulation of Steroid Receptor Coactivator-2 Modulates Estrogen-Responsive Genes and Stimulates Proliferation of MCF-7 Breast Cancer Cells

Ingvild S. Fenne1,2, Thomas Helland1,2, Marianne H. Flångeng1,2, Simon N. Dankel1,2, Gunnar Mellgren1,2, Jørn V. Sagen1,2*

1 Department of Clinical Science, University of Bergen, Bergen, Norway, 2 Hormone Laboratory, Haukeland University Hospital, Bergen, Norway

Abstract

The p160/Steroid Receptor Coactivators SRC-1, SRC-2/GRIP1, and SRC-3/AIB1 are important regulators of Estrogen Receptor alpha (ERα) activity. However, whereas the functions of SRC-1 and SRC-3 in breast tumourigenesis have been extensively studied, little is known about the role of SRC-2. Previously, we reported that activation of the cAMP-dependent protein kinase, PKA, facilitates ubiquitination and proteasomal degradation of SRC-2 which in turn leads to inhibition of SRC-2 coactivation of ERα and changed expression of the ERα target gene, pS2. Here we have characterized the global program of transcription in SRC-2-depleted MCF-7 breast cancer cells using short-hairpin RNA technology, and in MCF-7 cells exposed to PKA activating agents. In order to identify genes that may be regulated through PKA-induced downregulation of SRC-2, overlapping transcriptional targets in response to the respective treatments were characterized. Interestingly, we observed decreased expression of several breast cancer tumour suppressor genes (e.g., TAGLN, EGR1, BCL11b, CAV1) in response to both SRC-2 knockdown and PKA activation, whereas the expression of a number of other genes implicated in cancer progression (e.g., RET, BCA51, TFF3, OXCR4, ADM) was increased. In line with this, knockdown of SRC-2 also stimulated proliferation of MCF-7 cells. Together, these results suggest that SRC-2 may have an antiproliferative function in breast cancer cells.

Citation: Fenne IS, Helland T, Flångeng MH, Dankel SN, Mellgren G, et al. (2013) Downregulation of Steroid Receptor Coactivator-2 Modulates Estrogen-Responsive Genes and Stimulates Proliferation of MCF-7 Breast Cancer Cells. PLoS ONE 8(7): e70096. doi:10.1371/journal.pone.0070096

Editor: Karin Dahlman-Wright, Karolinska Institutet, Sweden

Received: May 7, 2013; Accepted: June 14, 2013; Published: July 30, 2013

Copyright: © 2013 Fenne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Funding for this project was provided by the Norwegian Cancer Society (https://kreftforeningen.no), The Western Norway Regional Health Authority (http://www.helse-bergen.no/forskning/samarbeidsorganet), KG Jebsen Center for Diabetes Research (http://www.uib.no/diabetes), Connie Gulborg Jansens Legat (http://www.uib.no/mofa/forskning/fond-og-legater), and Meltzerfondet, University of Bergen (http://meltzerfondet.no). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jørn.sagen@med.uib.no

Introduction

The Steroid Receptor Coactivator (SRC) family, also known as p160 proteins, consist of the three members, SRC-1 (NCOA1) [1], SRC-2 (NCOA2/GRIP1/TIF2) [2,3], and SRC-3 (NCOA3/AIB1/ACTR/RAC-3/pCIP/TRAM-1) [4–8]. Even though SRC-2 is functionally and structurally related to the other two SRC members, knockout studies in mice have shown that SRC-2 plays distinct functional roles in fertility and ductal branching in mammary gland [9,10], glucose- and lipid metabolism [11,12], regulation of bone mass [13], cardiac function [14] and progesterone-dependent cell cycle and immunity [15]. The SRC-specific functions are believed to be due to their tissue-specific expression levels, different affinities for various NRs, competition between NRs to recruit SRCs and between SRCs themselves for binding to NRs, and different post-translational modifications (PTMs) that regulate their protein levels and activity [16–18]. There is also evidence that SRC-2, in contrast to SRC-1 and SRC-3, has repressive effects on specific ER- and glucocorticoid receptor (GR) target genes in the presence of their respective ligands [19–22]. While the roles of SRC-1 and SRC-3 have been extensively studied in breast cancer, less is known about the function of SRC-2 in regulating genes involved in breast cancer progression. In contrast to SRC-2, SRC-1 and SRC-3 are frequently overexpressed in a subset of breast cancers, and correlate with a more aggressive tumour phenotype and poor prognosis and resistance to endocrine treatment [4,23–28]. Even though depletion of SRC-2 in MCF-7 cells has been shown to decrease estrogen-dependent ERα transactivation function, loss of SRC-2 does not seem to affect estrogen-dependent proliferation of MCF-7 cells [29]. This is in contrast to studies of SRC-3-depleted MCF-7 cells in which the estrogen-dependent proliferation of the cells was significantly reduced [29–32]. Molecular studies of each SRC in MCF-7 breast cancer cell suggest that the SRCs exhibit differential regulation of endogenous ER-target genes, indicating specific contributions of each SRC member to promote breast cancer [17,29,33,34]. In addition, distinct PTMs of the SRC members play a crucial role in controlling their intracellular levels and functions, which may have significant impact on breast carcinogenesis and response to endocrine treatment in breast cancer patients [18]. In previous studies we have demonstrated that activation of the cAMP-dependent protein kinase (PKA) signalling pathway targets SRC-2 coactivator function through its ubiquitination and proteasomal degradation. This in turn inhibits
SRC-2 and Estrogen-Responsive Genes in MCF-7 Cells

In the present study, our aim was to characterize the role of SRC-2 on global expression of genes in MCF-7 breast cancer cells. We also wanted to explore the effects of PKA-induced degradation of SRC-2 on the expression of genes involved in breast tumourigenesis. Interestingly, our data suggest that SRC-2 is important for the expression of various ER-target genes linked to breast cancer progression, including specific oncogenes and tumour suppressor genes. A subset of these genes was also found to be modulated through PKA-induced downregulation of SRC-2. Moreover, proliferation data suggested that knockdown (KD) of SRC-2 stimulated proliferation of MCF-7 cells. Taken together, our results suggest that SRC-2 play an important role in regulating expression of a subset of ER-target genes involved in proliferation of MCF-7 cells.

Materials and Methods

Cell Cultures

MCF-7 human breast adenocarcinoma cells and Human embryonic kidney 293T (HEK 293T) cells (ATCC) were grown at 37 °C and 5% CO₂, in Dulbecco’s modified Eagle’s medium (DMEM) (Cambrex, Verviers, Belgium) supplemented with 4.5 g/liter glucose, 2 mM L-glutamine, 10% foetal bovine serum (FBS), 100 units penicillin, 100 μg streptomycin. The MCF-7 cell medium also contained 1 μM insulin. For experiments MCF-7 cells were seeded in phenol red-free DMEM supplemented with 5% charcoal-stripped FBS.

Short Hairpin RNA (shRNA) Lentiviral Transduction

Five individual lentiviral pLKO.1-puro short hairpin (sh) RNA plasmids targeting different sequences on SRC-2/GRIP1 or SRC-3/AIB1 mRNA and a pLKO.1-puro empty vector control were purchased from Sigma Mission® RNAi (Sigma). To produce lentiviral stocks each plasmid was cotransfected with the lentiviral packaging plasmids psPAX2 and pMD2G into individual plates with HEK 293T cells using SuperFect (QIAGEN, Valencia, CA). The virus containing cell culture supernatants from each culture were collected 48 h after transfection and used for lentiviral transduction of individual MCF-7 cells cultures in the presence of 10 μg/ml puromycin for 3 weeks to obtain cells containing stably integrated shRNA.

RNA Extraction and Quantitative Real-time PCR

Total RNA from MCF-7 cells was extracted using RNeasy Mini kit (Qiagen, CA). 1 μg RNA was reverse transcribed using the cDNA synthesis kit (Roche, Basel, Switzerland). The real time quantitative reverse transcription (qRT)-PCR analyses were carried out using the LightCycler® RNA Master SYBR Green I kit in a LightCycler rapid thermal cycler system (Roche, Basel, Switzerland). The mRNA expression levels of target genes were quantified relative to the housekeeping gene TATA-binding protein (TBP). The primer sequences are provided in the Materials and Methods Supporting Information (Table S1).

Microarray Preparation of Samples

The shRNA-expressing MCF-7 cells were grown for three days in phenol red-free DMEM with 5% charcoal-stripped FBS and 10 nM 17β-estradiol. RNA was extracted from five independent plates of cells (replicates) expressing the pLKO.1-puro empty shRNA vector (Control shRNA), from five replicates of SRC-2

Figure 1. Downregulation of SRC-2 in MCF-7 cells induces distinct changes in global gene expression profiles. (A). Quantification of SRC-2 mRNA expression in shRNA lentivirus-infected MCF-7 cells. mRNA levels of SRC-2 in a MCF-7 cell line infected with shRNA targeting SRC-2 (SRC-2 shRNA) were compared to the expression in a control shRNA MCF-7 cell line (Ctr shRNA), and in a MCF-7 cell line transduced with shRNA lentivirus targeting SRC-3 (SRC-3 shRNA). The mRNA expression of SRC-2 is relative to TBP mRNA. The results are representative of at least three independent experiments. (B). Western blotting analyses of SRC-2-depleted MCF-7 cells. MCF-7 cells infected with shRNA lentivirus targeting SRC-2 (SRC-2 shRNA) or a negative control shRNA empty vector (Ctr shRNA), were grown in phenol red-free DMEM supplemented with charcoal stripped FBS (5%) and 17β-estradiol (10 nM) for two days. The Ctr shRNA cells were then treated with either Vehicle or 8-CPT-cAMP (150 μM), IBMX (50 μM) and forskolin (10 μM) (cAMP) for 24 hours. Immunoblotting was performed with anti-TIF2 antibody and anti-GAPDH antibody. The results shown are representative of at least three independent experiments. (C). Microarray analyses of five RNA samples isolated from five individual cell samples of shRNA control MCF-7 cells (Ctr shRNA), SRC-2 KD MCF-7 cells (SRC-2 shRNA) and control shRNA cells treated with cAMP elevating agents, as described in A. A Venn diagram shows the number of individual and overlapping sets of genes differentially expressed after SRC-2 KD (SRC-2 shRNA) and after treatment with cAMP elevating agents. To examine which genes were similarly differentially expressed between the two treated groups when compared to control, a SAM analysis with overlapping genes was performed. The fold change cut-off value ≥1.5, and q-value = 0, was used to determine differentially expressed genes.

doi:10.1371/journal.pone.0070096.g001
shRNA expressing cells (SRC-2 shRNA), and from five replicates of Control shRNA cells treated with 150 μM 8-parachlorophenylthio-cAMP (8-CPT-cAMP), 50 μM 3-isobutyl-1-methylxanthine (IBMX), and 10 μM forskolin for 24 hours. Sample preparations were balanced and randomized in each step of lysate collection, RNA extraction and labelling, and microarray hybridization. Microarray was performed using the Illumina HumanRef-8 v.3.0 Expression BeadChips.

**Microarray Analysis Using the Illumina Iscan System**

400 ng of total RNA from each cell sample (three biological groups, five samples within each group, 15 samples total) was biotin-labelled and amplified using the Illumina TotalPrep RNA amplification kit (version 0606, Ambion®; USA) and the Eppendorf Mastercycler (Eppendorf®; Germany). Quality and quantity measurement of the biotin-labelled cRNA were performed using the Agilent 2100 Bioanalyzer and the NanoDrop® ND-1000. 750 ng of cRNA was thereafter hybridized to the HumanRef-8 v.3.0 Expression BeadChips containing gene-specific probes at 38°C for 17 hours. The HumanRef-8 v.3.0 Expression BeadChip targets approximately 24500 genes derived from human genes in NCBI RefSeq database. The hybridization was performed according to the Whole Genome Gene Expression Direct Hybridization Assay Guide (Illumina Inc.). The fluorescense of the biotin-labelled cRNA was measured using the iScan Reader (Illumina Inc.). Analyses were performed at the Norwegian Microarray Consortium (NMC) Core Facility, University of Bergen, Norway.

**Microarray Data Extraction and Analysis**

The raw data from the microarray was imported into GenomeStudio Data Analysis Software (Illumina, Inc.) for quality controls. The control probes were then removed and a text file containing the signal and detection p-values per probe for all samples was created and imported to J-Express Pro software version 2009 (MolMine, Norway). Quality controls and analyses in J-Express were performed on quantile normalized and logarithmically transformed (base 2) signal intensity values [38]. Correspondence Analysis (CA) and hierarchical clustering with Pearson Correlation as a distance measure were applied to study global trends in the data and search for outliers within the sample groups [39]. Differentially expressed genes were detected through the Significance Analysis of Microarray (SAM) [40], and defined by fold change of at least 1.5 and q-value = 0. To search for over-represented functional categories among the differentially expressed genes, Protein ANalysis THrough Evolutionary Relationships (PANTHER) (version 7, http://www.pantherdb.org) was used to organize differentially expressed genes in categories representing biological functions and molecular functions. The Bonferroni correction for multiple testing was used to calculate p-values for the over-represented categories.

**Western Blotting**

Procedures for Western blotting are previously described (Hoang et al 2004). Primary antibodies used in the immunoblotting experiments were mouse monoclonal anti-TIF2 (BD Biosciences, San Jose, CA) and mouse monoclonal anti-GAPDH (Chemicon International, Temecula, CA).

**Cell Proliferation Assay**

Cell proliferation assays were performed using the xCELLigence system Real-Time Cell Analyzer (RTCA) DP instrument, as described by the manufacturer (Roche, Basel, Switzerland). MCF-7 cells were seeded in phenol red-free DMEM supplemented with 5% charcoal-stripped FBS for three days prior to the experiments. Background impedance was determined by incubating E-Plates with 100 mL cell medium for 30 minutes at 37°C and 5% CO₂, 8×10⁵ control shRNA cells and SRC-2 shRNA cells were then seeded into individual wells of the E-plates and treated with 10 nM 17β-estradiol or Vehicle. To activate the PKA signalling pathway, the cells were treated with 8-CPT-cAMP (150 μM), IBMX (50 μM) and forskolin (10 μM). The plates containing the cells

---

**Table 1. Overlapping decreased expression changes relative to control induced by SRC-2 KD and cAMP in MCF-7 cells.**

| Gene          | Definition                                           | Signal intensity | FC  |
|---------------|------------------------------------------------------|------------------|-----|
|               |                                                      | SRC-2 shRNA      | cAMP | Ctr shRNA | SRC-2 shRNA/Ctr shRNA | cAMP/Ctr shRNA |
| AKR1B10       | aldo-keto reductase family 1, member B10 (aldo reductase) | 255              | 257  | 507       | −1.98                 | −1.98          |
| ARHGGEF1      | Rho guanine nucleotide exchange factor (GEF) 19       | 420              | 415  | 632       | −1.50                 | −1.53          |
| BCL11B        | B-cell CLL/lymphoma 118 (zinc finger protein), transcript variant 1 | 232              | 313  | 570       | −2.46                 | −1.83          |
| CAV1          | caveolin 1, caveolea protein, 22Da                  | 3534             | 2946 | 5595      | −1.59                 | −1.91          |
| EGR1          | early growth response 1                              | 1159             | 1125 | 1799      | −1.55                 | −1.62          |
| KIKS          | kallikrein-related peptidease 5, transcript variant 1 | 345              | 292  | 598       | −1.74                 | −2.06          |
| KIKS          | kallikrein-related peptidease 5, transcript variant 2 | 244              | 226  | 416       | −1.72                 | −1.84          |
| KRT1          | keratin 1 (epidermolytic hyperkeratosis)             | 143              | 118  | 229       | −1.60                 | −1.94          |
| KRTS          | keratin 5                                           | 171              | 197  | 347       | −2.03                 | −1.76          |
| KRTDAP        | keratinocyte differentiation-associated protein       | 173              | 283  | 571       | −3.29                 | −2.02          |
| Protein S100-A9 | 5100 calcium binding protein A9 (calgranulin B)     | 308              | 644  | 1345      | −4.37                 | −2.11          |
| Protein S100-A8 | 5100 calcium binding protein A8                    | 242              | 530  | 1892      | −7.82                 | −3.58          |
| TAGLN         | Transgelin, transcript variant 2                    | 257              | 350  | 797       | −3.10                 | −2.28          |

Genes with FC ≥1.5 and q-value = 0 are shown in addition to their respective expression signals in the three microarray samples. cAMP, short-hairpin control MCF-7 cells treated with cAMP analogue (8-CPT-cAMP) and cAMP-elevating agents (IBMX and forskolin).

doi:10.1371/journal.pone.0070096.t001
were then incubated at room temperature for 30 minutes before placing them into the RTCA-unit. Cell growth was measured for 120 hours by monitoring the impedance every 15 minutes. Impedance is represented by cell index (CI) and was calculated as follows: $\frac{Z_i - Z_0}{15W}$, where $Z_i$ is the impedance at an individual time-point, and $Z_0$ is the background impedance. Average CI was calculated from a minimum of 2–4 wells per time-point and per experiment.

**Results**

Loss of SRC-2 in MCF-7 Breast Cancer Cells Induces Distinct Changes in the Global Gene Expression

Previously we have shown that activation of PKA leads to increased ubiquitination and subsequent degradation of SRC-2, which in turn leads to inhibition of ERα transactivation function [35,36]. Here we wanted to study the role of SRC-2 and the functional relevance of the PKA-mediated regulation of SRC-2 on gene expression in MCF-7 human breast cancer cells. Thus, we analysed global gene expression profiles of MCF-7 cells after either KD of SRC-2 or treatment with cAMP elevating agents. As shown in Figure 1A, there was approximately 65% reduction in SRC-2 mRNA expression after KD of SRC-2 (SRC-2 shRNA) compared to the control shRNA MCF-7 cells (Ctr shRNA), which was not found in a cell line expressing shRNA against SRC-3. Western blotting analyses confirmed successful KD of SRC-2 (Figure 1B). In order to activate PKA in the Ctr shRNA cells, they were treated with a cAMP analogue (8-CTP-cAMP) and cAMP elevating agents (IBMX and forskolin) for 24 hours. This time point was optimal to achieve degradation of SRC-2. As previously shown [36,41], activation of PKA resulted in a significant reduction in SRC-2 protein level.

Five samples of RNA from each of the three different treatments (Ctr shRNA, SRC-2 shRNA and cAMP) were subjected to microarray analysis. Correspondence Analysis which displays the differences in global gene expression in a two-dimensional plot revealed a distinct separation between the three groups and no outliers, indicating differential expression of genes at the global level (Figure S1). Using a fold change $\geq 1.5$ and a q-value $= 0$, a total number of 383 genes (194 downregulated and 189 upregulated) were differentially expressed in the SRC-2 KD cells (Tables S2 and S3), whereas the cAMP-treated cells showed 210 differentially expressed genes (68 downregulated and 142 upregulated) (Figure 1C), (Tables S4 and S5).

**Overlap of Gene Expression Changes Induced by SRC-2 Knockdown and cAMP**

In order to study genes that could potentially be regulated through PKA-mediated downregulation of SRC-2, we searched...
for overlapping differentially expressed genes after SRC-2 KD or elevation of cAMP. As shown in the Venn diagram in Figure 1C, the expression of 12 genes decreased, whereas 12 genes showed increased expression both after SRC-2 KD or cAMP treatment (Table 1 and Table 2).

To gain insight into the functions of the genes changed by both SRC-2 depletion and cAMP elevation, we performed gene ontology analyses of the overlapping genes using the PANTHER classification system. We observed that several of these genes were involved in the PANTHER Biological Process categories Cell cycle (e.g. RET, S100P, KLK5, S100A8, S100A9, and EGR1), Cell motility (e.g. CXCR4 RET, TFF3, S100P, S100A8 and S100A9), Immune response (e.g. CXCR4, S100P, S100A8, S100A9, TFF3, KLK5, RET and TFF1), Signal transduction (e.g. CXCR4 RET, TFF3, S100P, S100A8, S100A9 and CAV1) and Metabolic processes (e.g. RET, TFF1, AKR1C2, KLK5, AKR1B10, BCL11B and EGR1) (data not shown). In order to increase the number of overlapping genes to be included in the PANTHER analyses but simultaneously maintain a low chance of false positive hits, fold change cut-off value was lowered from 1.5 to 1.3 (q-value = 0). Our analyses revealed 124 genes involved in cell communication was enhanced.

Depletion of SRC-2 Downregulates Tumour Suppressor Genes and Upregulates Oncogenes

To confirm that gene expression changes observed in the microarray data were representative of the original samples, a subset of the differentially expressed overlapping genes were selected for validation by qRT-PCR analysis (Table 3). Based on the fact that little is known about the role of SRC-2 in breast tumourigenesis, genes that have been associated with breast cancer were selected for validation by qRT-PCR. The five genes showing decreased expression after SRC-2 KD and PKA activation compared to control, EGR1, TAGLN, CAV1, BCL11b and AKR1B10, together with five overlapping genes showing increased expression, RET (tv2 and tv4), BCAS1, TFF3, ADM, CXCR4, were chosen for validation. EGR1, CAV1, TAGLN and BCL11b are estrogen-responsive genes described as tumour suppressors in breast cancer [42–45], whereas the upregulated genes are estrogen-responsive genes described as breast cancer oncogenes (RET, BCAS1, TFF3) [46–48] or known to stimulate breast cancer metastasis and progression (CXCR4, ADM) [49,50]. We observed that the mRNA expression of these genes was reversed by overexpression of SRC-2 in MCF-7 cells (data not shown). As shown in Table 3, the qRT-PCR validation results were highly consistent with the microarray results, suggesting that SRC-2 is regulating estrogen-responsive genes involved in breast tumourigenesis. The results indicate that downregulation of SRC-2 mediates decreased expression of several tumour suppressor genes, whereas the expression of genes involved in oncogenesis were increased.

### Table 2. Overlapping increased expression changes relative to control induced by SRC-2 KD and cAMP in MCF-7 cells.

| Gene            | Definition                          | Signal Intensity | FC |
|-----------------|-------------------------------------|------------------|----|
| ADM             | adrenomedullin                      | 336              | 1.90 | 1.54 |
| AKR1C2          |aldo-keto reductase family 1, member C2, transcript variant 1 | 10519            | 1.57 | 1.51 |
| BCAS1           |breast carcinoma amplified sequence 1 | 474              | 2.07 | 2.39 |
| CXCR4           |chemokine (C-X-C motif) receptor 4, transcript variant 2 | 411              | 2.19 | 1.51 |
| C9orf152        |chromosome 9 open reading frame 152 | 776              | 1.74 | 2.03 |
| FAM64A          |family with sequence similarity 46, member A | 1647            | 4.00 | 4.00 |
| S100A8          |(hypothetical protein LOC130576), LY6/PLAUR domain containing 6B | 1361            | 1.86 | 1.64 |
| NUCB2           |nucleobindin 2                      | 625              | 1.50 | 1.87 |
| RET             |ret proto-oncogene, transcript variant 4 | 986              | 1.83 | 1.65 |
| RET             |ret proto-oncogene, transcript variant 2 | 1045            | 1.99 | 2.04 |
| S100P           |S100 calcium binding protein P      | 3980             | 3.12 | 4.41 |
| TFF3            |trefoil factor 3 (intestinal)       | 17129            | 1.68 | 1.72 |
| TFF3            |tissue factor pathway inhibitor, transcript variant 2 | 537              | 1.10 | 1.19 |
| TFF1            |tissue factor pathway inhibitor, transcript variant 1 | 416              | 1.51 | 1.70 |

Genes with FC ≥1.5 and q-value = 0 are shown in addition to their respective expression signals in the three microarray samples. cAMP, short-hairpin control MCF-7 cells treated with cAMP analogue (8-CPT-cAMP) and cAMP-elevating agents (IBMX and forskolin). doi:10.1371/journal.pone.0070096.t002
Estrogen-responsive Genes Regulated Through cAMP/ PKA-mediated Degradation of SRC-2

Next we wanted to verify whether the expression of the selected overlapping genes was regulated through PKA-mediated degradation of SRC-2. Thus, qRT-PCR was used to quantify the mRNA expression changes of selected genes in control MCF-7 cells and in SRC-2-depleted cells in response to treatment with PKA activating agents (Figure 3). The relative increase in mRNA expression of *BCAS1*, *RET* (tv2) and *RET* (tv4) due to PKA activation (cAMP) observed in the control shRNA cells was diminished or absent in the SRC-2 shRNA cells. In cells with reduced SRC-2 level, adding PKA activating agents did not result in any further increase in the expression of these three genes, suggesting that the cAMP effect is mediated via downregulation of SRC-2. In contrast, *TFF3* mRNA levels were increased by PKA in both cell lines, suggesting that this gene is also regulated by PKA via an SRC-2 independent pathway (Figure 3). The relative PKA-induced downregulation of *EGR1*, *BCL11b* and *TAGLN*, but not *CAV-1* was counteracted by SRC-2 KD. Together, these results suggested that expression of *BCAS1*, *RET*, *EGR1*, *BCL11b* and *TAGLN* are regulated through PKA-induced SRC-2 degradation (Figure 3), whereas PKA regulates the expression of *TFF3* and *CAV1* independently of SRC-2 degradation.

Depletion of SRC-2 Stimulates Breast Cancer Cell Proliferation

Since our results indicated that KD of SRC-2 changes the expression of estrogen-responsive genes known to be involved in carcinogenesis, we wanted to examine whether KD of SRC-2 affected the real time growth of MCF-7 cells by using the xCELLigence System. We also examined the growth of control shRNA cells and SRC-2 shRNA cells treated with cAMP analogue...
and cAMP-elevating agents. The cell proliferation was monitored both in the absence and presence of 17β-estradiol. Interestingly, MCF-7 cells with reduced level of SRC-2 showed a significant increase in cell proliferation compared to the control shRNA cell line. This was observed both in the presence and absence of 17β-estradiol (Figures 4A and 4B). Moreover, we observed that MCF-7 cell growth increased significantly after treatment with the PKA-activating agents. The cAMP-stimulated growth was also observed in the SRC-2 KD cells (Figures 4A and 4B). MCF-7 cells treated with both SRC-2 shRNA and PKA-activating agents showed the most pronounced cell proliferation, suggesting that PKA has an effect on proliferation independent of SRC-2 degradation. Together, these data suggest that downregulation of SRC-2 induce proliferation of MCF-7 cells.

**Discussion**

Several studies have examined how the different members of the SRC coactivator family promote carcinogenesis. The three SRCs are regulated by multiple upstream signalling pathways and changes in their protein levels or activity can effectively modulate gene expression. Unlike SRC-1 and SRC-3, which are overexpressed in different types of cancers, there are few reports regarding a role of SRC-2 in oncogenesis [51,52]. In the present study, we explored the potential function of SRC-2 in MCF-7 breast cancer cells, and the role of PKA-mediated degradation of SRC-2 by characterization of the transcriptomes of SRC-2-depleted MCF-7 cells and of cells treated with PKA-activating agents. We observed that downregulation of SRC-2 induces significant changes in the expression of several estrogen-responsive genes involved in breast cancer progression. Consistent with these findings, we observed that depletion of SRC-2 in MCF-7 cells clearly stimulated proliferation of the cells. Together, the results suggest an antiproliferative role of SRC-2 in MCF-7 cells.

A recent study also demonstrated that low levels of SRC-2 expression in hepatocellular carcinoma patients were associated with poor prognosis, and RNAi-mediated knockdown of SRC-2 in diethylnitrosamine-treated mice promoted liver tumourigenesis [53]. Moreover, it has been reported that enhanced expression of SRC-2 in malignant pleural mesothelioma (MPM) tumour cells is associated with improved prognosis [54]. SRC-2 is implicated in various cancers including colon, prostate, endometrial, liver, and astrocytic brain cancer [53,55–58]. In breast tumour tissue, endocrine therapy has also been shown to induce the expression of SRCs [59,60]. Still, there are few reports regarding the contribution of SRC-2 to cell growth and its role in regulating genes involved in cell proliferation and cancer progression. Our findings suggest an inhibitory role of SRC-2 in breast tumourigenesis which differs from the established oncogenic function of two other SRC family members. A recent study demonstrated that SRC-3, but not SRC-2, is required for estradiol-dependent growth of breast cancer cells, which is in agreement with our observations [29]. Another report have shown that SRC-3, in contrast to SRC-2, stimulates proliferation of androgen-dependent and androgen-independent prostate cancer cell and tumour growth [61], indicating a different role of SRC-2 in these types of cancer. The reason for these apparent differences in growth regulation between SRC family members is not clear. However, it has been shown that the different SRCs have tissue-specific functions [62], as well as gene-specific roles in regulating estrogen-responsive genes in breast cancer cells [17,29,34]. It has also been demonstrated that recruitment of a particular member of the SRC family to a DNA-associated transcription factor is determined by the level of expression of that particular SRC, and PTMs may alter the availability of SRCs [33].

Activation of the PKA-signalling pathway specifically inhibits the coactivator function of SRC-2 in MCF-7 cells by promoting its ubiquitination and degradation and thereby reducing ERF transactivation function [35,36]. In the present study we demonstrated that downregulation of SRC-2 by PKA modulates the expression of several estrogen-responsive genes involved in breast tumourigenesis, including RET, BCAS1, EGR1, BCL11B and TAGLN, indicating that PKA signalling through SRC-2 could be implicated in breast cancer progression. Moreover, functional analyses of differentially expressed genes after cAMP-treatment revealed enhanced expression of genes involved in cell cycle and cell signalling processes, as well as genes encoding signalling molecules such as growth factors (data not shown). In line with this, we observed enhanced proliferation of MCF-7 cells treated with PKA activating agents. Adding cAMP elevating agents to the

| Table 3. Validation of selected genes by qRT-PCR. |
|-----------------------------------------------|
| **Gene** | **Microarray** | **Q-rt-PCR** | **Microarray** | **Q-rt-PCR** |
| SRC-2 shRNA/Ctr | SRC-2 shRNA/Ctr | 95% CI | cAMP/Ctr shRNA | cAMP/Ctr shRNA | 95% CI |
| shRNA | cAMP/Ctr shRNA | | shRNA | 95% CI | shRNA | cAMP/Ctr shRNA | 95% CI |
| ADM | 1.90 | 1.54 | 2.81 | 1.16–6.81 | 2.10 | 0.95–4.63 |
| BCA51 | 2.07 | 2.39 | 4.21 | 1.74–10.20 | 5.11 | 2.74–9.54 |
| CXCR4 | 2.19 | 1.51 | 4.97 | 2.40–10.30 | 2.55 | 1.89–3.44 |
| RET (tv4) | 1.839 | 1.65 | 2.53 | 1.22–5.18 | 2.14 | 1.17–3.89 |
| RET (tv2) | 1.20 | 2.04 | 1.88 | 0.75–4.38 | 1.63 | 0.88–3.02 |
| TFF3 | 1.68 | 1.72 | 2.46 | 1.06–5.72 | 2.44 | 1.46–3.78 |
| AKR1B10 | −1.98 | −1.98 | 0.46 | 0.24–0.88 | 0.39 | 0.27–0.55 |
| BCL11B | −2.45 | −1.83 | 0.20 | 0.11–0.40 | 0.44 | 0.24–0.80 |
| CAV1 | −1.59 | −1.91 | 0.57 | 0.33–0.99 | 0.45 | 0.37–0.56 |
| EGR1 | −1.55 | −1.62 | 0.82 | 0.41–1.66 | 0.66 | 0.34–1.27 |
| TAGLN | −3.10 | −2.28 | 0.22 | 0.14–0.34 | 0.35 | 0.24–0.44 |

Fold change values from the microarray analyses compared to quantification of mRNA expression by qRT-PCR presented as geometric mean with 95% confidence intervals (CI), n = 5. cAMP, short-hairpin control MCF-7 cells treated with cAMP analogue (8-CPT-cAMP) and cAMP-elevating agents (IBMX and forskolin). doi:10.1371/journal.pone.0070096.t003
SRC-2-silenced cells resulted in the most pronounced proliferation pattern. The gene expression and proliferation data suggest that PKA promotes tumourigenesis via both SRC-2-dependent as well as -independent mechanisms. PKA is known to be implicated in initiation and progression of many tumours, but the mechanism by which PKA promote cancinogenesis is not clear [63]. The cAMP/PKA signalling pathway appears to have both proliferative and anti-proliferative effects on breast cancer cell growth [64–67], and various cAMP analogues have also been reported to exert different effects on breast cancer cell growth which may be due to differences in their mechanisms of action [67].

Even though SRC-2 is classified as a coactivator we observed that several genes also were up-regulated due to reduced SRC-2 expression, suggesting a repressive effect of SRC-2 on the expression of some estrogen-responsive genes in breast cancer cells. However, the mechanism by which estrogen represses gene expression is unknown. Studies have shown that SRC-2 in contrast to SRC-1 and SRC-3, possess a unique repression domain encompassing GRIP1 amino acids 767–1006 utilized in repression of GR-mediated inhibition of target gene expression [19]. It has been suggested that the enhancing- or repressive effect of SRC-2 on gene expression could be tissue specific and also to be dependent on the regulatory context of the target gene promoter.

Figure 4. Downregulation of SRC-2 promotes proliferation of MCF-7 cells. MCF-7 cells with KD of SRC-2 (SRC-2 shRNA) and control shRNA MCF-7 cells (Ctr shRNA) grown in phenol red-free DMEM supplemented with charcoal stripped FBS (5%) for three days, were seeded in E-Plate 16 and treated with either Vehicle or 8-CPT-cAMP (150 μM), IBMX (50 μM) and forskolin (10 μM) (cAMP), in the absence or presence of 17β-estradiol (E2, 10 nM) (A and B, respectively). Proliferation of the cells was measured by using the xCELLigence system monitoring cellular impedance continuously for 120 hours. The results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0070096.g004
Since we observed that depletion of SRC-2 led to enhanced expression of several genes, including ERα-target genes, it is possible that SRC-2 may also function as a transcriptional corepressor of ERα in breast cancer cells.

Some studies have shown that the SRCs are able to compensate for the loss of individual SRC-member [68,69]. However, a recent ChIP-sequencing mapping study of the global chromatin binding sites of individual SRCs in MCF-7 cells, revealed limited degree of redundancy between the different SRCs [34], which has also been seen in a study comparing the role of the three SRC family members on metabolism in different organs [70]. By analysing the expression of selected SRC-2- and PKA-regulated (overlapping) genes in SRC-3-depleted MCF-7 cells, we confirmed a specific regulation of these genes by SRC-2 (data not shown). In addition, analyses of transcription factor binding sites in the promoter regions of the selected overlapping genes showed enriched NR2F binding motifs in their promoters, which have shown by others to be exclusively found for SRC-2 target genes [34]. Thus, we believe that the oncogenic phenotype observed in the SRC-2-depleted cells is SRC-2 specific and not caused by compensatory effects of the other SRCs.

In summary, our data suggest that reduced levels of SRC-2 in breast cancer cells modulates the expression of estrogen-regulated genes leading to enhanced proliferation of breast cancer cells, suggesting that SRC-2 has antiproliferative properties in breast cancer cells.

Supporting Information

Figure S1: Correspondence analysis (CA) plot showing projection of microarray samples. Ctr shRNA: pink squares, SRC-2 shRNA: green diamonds, cAMP: purple circles. The first principle component is shown on the x-axis and the second principle component is displayed on the y-axis. All three groups of samples are separated along the first principle component (22.706% component variance). The second principle component (15.192% component variance) separates the two groups of treated samples (SRC-2 shRNA and cAMP) from the control group sample (Ctr shRNA).

References

1. Onate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354–1357.
2. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR (1996) GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A 93: 4948–4952.
3. Voegel J, Heine MJ, Zechel C, Chambron P, Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15: 3667–3675.
4. Ametek SI, Kononen J, Walker RL, Assen D, Tanner MM, et al. (1997) ABI1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 273: 965–968.
5. Chen H, Lin RJ, Schiltz RL, Chakkaravar蒂 D, Nash A, et al. (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multienzyme activation complex with P/CAF and CBP/p300. Cell 90: 569–580.
6. Li H, Gomes P, Chen JD (1997) RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A 94: 8479–8484.
7. Takeshita A, Cardona GR, Kobuschi N, Suen CS, Chin WW (1997) TRAM-1, A novel 160-kDa thyroid hormone receptor coactivator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 272: 27629–27634.
8. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, et al. (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387: 677–684.
9. Gehin M, Mark M, Dienfelf C, Diedrich A, Gronemeyer H, et al. (2002) The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22: 5925–5937.
10. Mukherjee A, Amato P, Craig-Alldred D, DeMayo FJ, O’Malley BW, et al. (2007) Steroid receptor coactivator 2: an essential coregulator of progesterin-induced uterine and mammary morphogenesis. Ernst Schering Found Symp Proc 55–76.
11. Jeong JW, Kwak I, Lee KY, White LD, Wang XP, et al. (2006) The genomic analysis of the impact of steroid receptor coactivatorsolation on hepatic metabolism. Mol Endocrinol 20: 1138–1152.
12. Picard F, Gehin M, Annicott F, Roche S, Champy MF, et al. (2002) SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111: 931–941.
13. Møller U, Monrose DG, Fraser TG, Rosen CJ, et al. (2009) Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem 284: 10767–10777.
14. Reineke EL, York B, Stashi E, Chen X, Tsimelzon A, et al. (2012) SRC-2 Coactivator Deficiency Decreases Functional Reserve in Response to Pressure Overload of Mouse Heart. PLoS One 7: e53393.
15. Jeong JW, Lee KY, Han SJ, Aronow BJ, Lydon JP, et al. (2007) The p160 steroid receptor coactivator 2, SRC-2, regulates murine endometrial function and modulates endometrial estrogenic effects on uterine and mammary morphogenesis. Ernst Schering Found Symp Proc: 55–76.
16. Li X, Wong J, Tsai SY, Tsai MJ, O’Malley BW (2003) Progestrone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23: 3763–3773.
17. Won Jeong K, Chodankar R, Purcell DJ, Bittencourt D, Stallcup MR (2012) Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol 26: 955–966.
18. Li S, Shang Y (2007) Regulation of SRC family coactivators by post-translational modifications. Cell Signal 19: 1101–1112.

Table S1: Primer sequences used for Q-rt-PCR.

Table S2: Downregulated differentially expressed genes induced by SRC-2 shRNA. FC ≥1.5, q-value = 0.

Table S3: Upregulated differentially expressed genes induced by SRC-2 shRNA. FC ≥1.5, q-value = 0.

Table S4: Downregulated differentially expressed genes induced by cAMP. FC ≥1.5, q-value = 0.

Table S5: Upregulated differentially expressed genes induced by cAMP. FC ≥1.5, q-value = 0.

Table S6: Overlapping downregulated differentially expressed genes induced by SRC-2 shRNA and cAMP. FC ≥1.3, q-value = 0.

Table S7: Upregulated overlapping differentially expressed genes induced by SRC-2 shRNA and cAMP. FC ≥1.3, q-value = 0.

Abbreviations S1.

Acknowledgments

Technical assistance from Carol Cook and Anita Ivarsflaten is highly appreciated. We thank the staff at the Norwegian Bioinformatics Platform and the Norwegian Microarray Consortium, University of Bergen Core Facility for expert assistance with analyses.

Author Contributions

Conceived and designed the experiments: ISF TH JVS GM. Performed the experiments: ISF TH MHF SND GM JVS. Analyzed the data: ISF TH. Technical assistance from Carol Cook and Anita Ivarsflaten is highly appreciated. We thank the staff at the Norwegian Bioinformatics Platform and the Norwegian Microarray Consortium, University of Bergen Core Facility for expert assistance with analyses.

Supporting Online Material

Figure S1 Correspondence analysis (CA) plot showing projection of microarray samples. Ctr shRNA: pink squares, SRC-2 shRNA: green diamonds, cAMP: purple circles. The first principle component is shown on the x-axis and the second principle component is displayed on the y-axis. All three groups of samples are separated along the first principle component (22.706% component variance). The second principle component (15.192% component variance) separates the two groups of treated samples (SRC-2 shRNA and cAMP) from the control group sample (Ctr shRNA).
19. Rogatsky I, Luettek IF, Leitman DC, Yamamoto KR (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci U S A 99: 16761–16766.

20. Cynober A, Taagazheki-Foster C, Taiz P, Sakai T, Kohler S, Fox MS, et al. (2006) Distinct roles of undamaged and liganded estrogen receptors in transcriptional repression. Mol Cell 21: 555–564.

21. Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 co-activator activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20: 6071–6083.

22. Uehlehn NH, Barish GD, Yu RT, Downes M, Karanam S, et al. (2013) Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cotumors. Mol Cell 49: 138–171.

23. Fleming JF, Myers E, Kelly G, Crotty TB, McDermott EW, et al. (2004) Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 57: 1069–1074.

24. Murphy LC, Simon SL, Parkes A, Leygue E, Zottes H, et al. (2000) Altered subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 275: 23763–23768.

25. Li JJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, et al. (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276: 23753–23760.

26. Xiu J, Wu RC, O’Malley BW (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615–630.

27. Zhang H, Yi X, Sun X, Yin N, Shi B, et al. (2004) Differential gene regulation by the SRC family of coactivators. Gene Dev 18: 1753–1763.

28. Zwaan W, Theodoron V, Kok M, Canisius S, Linn S, et al. (2011) Oestrogen receptor-α factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO J 30: 4764–4776.

29. Fennes S, Hoang T, Hauglid M, Sagen JV, Lien EA, et al. (2008) Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 5’-3’ cyclic adenosine 5’-monophosphate-dependent protein kinase. Endocrinology 149: 4336–4345.

30. Hoang T, Hauglid M, Sagen JV, Lien EA, et al. (2008) cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 279: 49120–49130.

31. Hoang T, Fennes S, Madsen A, Buskovic O, Johannesen M, et al. (2013) cAMP Response Element-Binding Protein Interacts With and Stimulates the Proteasomal Degradation of the Nuclear Receptor Coactivator GRIP1. Endocrinology 154: 1513–1527.

32. Horikawa Y, Iwata Y, Asa K, Nishikawa M, Speed TP (2000) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 16: 185–193.

33. Fellenberg K, Hauser NC, Boers B, Neutzen M, Honefajl JD, et al. (2001) Correspondence analysis applied to microarray data. Proc Natl Acad Sci U S A 98: 10761–10766.

34. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays. Proc Natl Acad Sci U S A 98: 10743–10748.

35. Hoang T, Fenne IS, Madsen A, Bozickovic O, Johannessen M, et al. (2013) Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cotumors. Mol Cell 49: 138–171.

36. Fenne IS, Hoang T, Hauglid M, Sagen JV, Lien EA, et al. (2008) Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 5’-3’ cyclic adenosine 5’-monophosphate-dependent protein kinase. Endocrinology 149: 4336–4345.

37. Hoang T, Fenne IS, Cook C, Borud B, Bakke M, et al. (2004) cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 275: 23763–23768.